News

« Previous 12345 Next »
Viewing Page 1 of 5 | Showing Results 1 - 10 of 42

Phase 1 trials advance promising new immunotherapies for cancer

March 01, 2019

Phase 1 studies are the springboard for advancing new cancer treatments. Through phase 1 studies, the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies, including these two recently opened studies.

Immunotherapy studies open for triple-negative breast cancer

January 22, 2019

Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. Providence Cancer Institute, a leader in immunotherapy research, is actively investigating options for this aggressive cancer.

Melanoma study: are two immunotherapies better than one?

December 07, 2018

A newly opened Phase 3 study at Providence Cancer Institute hopes to shed new light on the benefits of two immunotherapies, nivolumab and NKTR-214, for patients with advanced melanoma.

New immunotherapy options for liver cancer

November 29, 2018

Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver cancer patients, including two new studies investigating checkpoint inhibitors.

CAR T-cell trial offers promising second-line therapy for B-cell lymphoma

October 17, 2018

Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute.

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed!

October 02, 2018

The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed! This new space allows us to expand and consolidate our outpatient cancer services in the new Providence Cancer Institute Franz Clinic.

PARP-inhibitor study opens for BRCA+, HER2- breast cancer

October 01, 2018

PARP inhibitors are emerging as “one of the promising breakthroughs in experimental oncology,” and have the potential to offer significant benefits for women with BRCA-mutant breast cancers.

Providence Cancer Institute Franz Clinic offers expanded outpatient services

September 14, 2018

From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.

Providence remembers Elsie Franz Finley

August 20, 2018

PROVIDENCE CANCER INSTITUTE – It is with deep sadness we announce the passing of Elsie Franz Finley who died Aug. 14, 2018. She was 97 years old.

Clinical trials offer new options for advanced bladder/urothelial cancers

August 17, 2018

Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other immunotherapies can be most beneficial to patients with this difficult-to-treat disease. At Providence Cancer Institute, four new studies of different immunotherapy approaches are now open to patients.

« Previous 12345 Next »
Viewing Page 1 of 5 | Showing Results 1 - 10 of 42